PerkinElmer Announces Agreement with Predictive Diagnostics That Allows for Comprehensive Biomarker Platform
New Biomarker Platform Critical In Accelerating Drug Development
Under the terms of the agreement, PerkinElmer will provide access to PDI's proprietary Biomarker Amplification Filter (BAMF(TM)) Technology customized for PerkinElmer's prOTOF(TM) 2000 MALDI O-TOF mass spectrometer to create the "industry standard" platform for biomarker discovery and analysis. PerkinElmer's Life and Analytical Sciences sales and marketing team will exclusively offer PDI's BAMF Technology services to leading pharmaceutical companies and major research institutions.
PDI's BAMF(TM) Technology is a comprehensive suite of in silico machine learning technologies and advanced informatics tools that use a simple blood test for the discovery of biomarker fingerprints to diagnose diseases utilizing high-resolution mass spectrometry data. PDI has developed its BAMF Technology for use in serum-based tests for early diagnosis of cancer and other life-threatening diseases. "Predictive Diagnostics is a recognized leader in biomarker analysis software. Their proprietary set of algorithms and informatics capabilities will complement our mass spectrometry and proprietary consumables offerings and complete our total solution for biomarker discovery and screening." said Peter Coggins, Ph.D., president of PerkinElmer Life and Analytical Sciences. "We believe this solution will be enabling technology for our pharmaceutical, biotech, and academic customers in the proteomic biomarker field."
PerkinElmer's prOTOF 2000 is part of the company's High Content Proteomics solution, a comprehensive approach to proteomics research pioneered by PerkinElmer. Using advanced, innovative technologies, like the prOTOF(TM) 2000 MALDI O-TOF, PerkinElmer has developed a suite of tools that achieve maximum meaningful data from any sample, improving results and reproducibility. "PerkinElmer is the leader in state-of-the-art proteomic hardware and advanced purification solutions needed for advanced proteomic biomarker analysis," said Kevin Ryan, CEO of Predictive Diagnostics. "We are confident that the combined strength of PerkinElmer's proteomic hardware and PDI's portfolio of discovery and diagnostic solutions will add significant value to our pharmaceutical and life sciences customers."
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Spectroscopy
Investigation with spectroscopy gives us unique insights into the composition and structure of materials. From UV-Vis spectroscopy to infrared and Raman spectroscopy to fluorescence and atomic absorption spectroscopy, spectroscopy offers us a wide range of analytical techniques to precisely characterize substances. Immerse yourself in the fascinating world of spectroscopy!
Topic World Spectroscopy
Investigation with spectroscopy gives us unique insights into the composition and structure of materials. From UV-Vis spectroscopy to infrared and Raman spectroscopy to fluorescence and atomic absorption spectroscopy, spectroscopy offers us a wide range of analytical techniques to precisely characterize substances. Immerse yourself in the fascinating world of spectroscopy!
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.